Add to ORKGThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited
Full copyright for enhanced digital features is owned by the authors. Article full text The fu...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Abstract Background Real-world impact of extended-release formulations of oral drugs should ideally ...
Eva-Maria Hametner, Klaus Seppi, Werner PoeweDepartment of Neurology, Innsbruck Medical University, ...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
Angelo Antonini¹, Daniela Calandrella²¹Department for Parkinson&rsquo...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
<p>The paper considers a clinical case of early-stage mixed Parkinson’s disease (PD) with significan...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
Pramipexol retard is the newest drug for the treatment of Parkinson's disease. The prolonged release...
Full copyright for enhanced digital features is owned by the authors. Article full text The fu...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Abstract Background Real-world impact of extended-release formulations of oral drugs should ideally ...
Eva-Maria Hametner, Klaus Seppi, Werner PoeweDepartment of Neurology, Innsbruck Medical University, ...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
Angelo Antonini&sup1;, Daniela Calandrella&sup2;&sup1;Department for Parkinson&rsquo...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
<p>The paper considers a clinical case of early-stage mixed Parkinson’s disease (PD) with significan...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
Pramipexol retard is the newest drug for the treatment of Parkinson's disease. The prolonged release...
Full copyright for enhanced digital features is owned by the authors. Article full text The fu...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Abstract Background Real-world impact of extended-release formulations of oral drugs should ideally ...